New hope for advanced breast cancer: drug combo trial launches
NCT ID NCT05860465
First seen Jan 18, 2026 · Last updated May 15, 2026 · Updated 17 times
Summary
This study tests a new drug called SPH4336 combined with hormone therapy for people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has gotten worse after standard treatment. About 254 participants will receive the combination to see if it shrinks tumors or delays cancer growth. The goal is to offer a new option for controlling the disease when other treatments stop working.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Cancer Hospital, Sun Yat-sen University
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Anyang Cancer Hospital
RECRUITINGAnyang, He'nan, 455001, China
Contact
-
First Affiliated Hospital of Kunming Medical University
RECRUITINGKunming, China
Contact
-
Fujian Cancer Hospital
RECRUITINGFuzhou, China
Contact
-
General Hospital of Ningxia Medical University
RECRUITINGYinchuan, Ningxia, 750003, China
Contact
-
Harbin Medical University cancer Hospital
RECRUITINGHarbin, Heilongjiang, 150081, China
Contact
-
Jiangsu Cancer Hospital
RECRUITINGNanjing, Jiangsu, 210009, China
Contact
-
Jiangsu Province Hospital
RECRUITINGNanjing, Jiangsu, 210029, China
Contact
-
Jilin Cancer Hospital
RECRUITINGChangchun, Jilin, 130012, China
Contact
-
Liuzhou people's Hospital
RECRUITINGLiuzhou, Guangxi, 545026, China
Contact
-
Peking Union Medical College Hospital
RECRUITINGBeijing, 100730, China
Contact
-
Shenzhen Hospital of University of Hong Kong
RECRUITINGShenzhen, China
Contact
-
The First Affiliated Hospital of Bengbu Medical College
RECRUITINGBengbu, China
Contact
-
The First Affiliated Hospital of Henan University of Science and Technology
RECRUITINGLuoyang, He'nan, 450052, China
Contact
-
The First Affiliated Hospital of Xi'an Jiao Tong University
RECRUITINGXi’an, Shanxi, 710061, China
Contact
-
The First Hospital of China Medical University
RECRUITINGShenyang, Liaoning, 110002, China
Contact
-
The Fourth Hospital of Hebei Medical University
RECRUITINGShijiazhuang, Hebei, 050011, China
Contact
-
The second people's hospital of neijiang
RECRUITINGNeijiang, Sichuan, 641199, China
Contact
-
Tianjin Medical University Cancer Institute & Hospital
RECRUITINGTianjin, China
Contact
-
Xiangyang Cancer Hospital
RECRUITINGWuhan, Hubei, 441021, China
Contact
-
Yunnan Cancer Hospital
RECRUITINGKunming, Yunnan, 650118, China
Contact
-
Zhejiang cancer Hospital
RECRUITINGHangzhou, Zhejiang, 310005, China
Contact
Conditions
Explore the condition pages connected to this study.